Key facts
- This page summarizes Christopher Gerard's Form 4 filing for AMEDISYS INC (AMED).
- 4 reported transactions and 0 derivative rows are listed below.
- Accepted by SEC: 04 Aug 2021, 21:01.
Christopher Gerard - 02 Aug 2021 Form 4 Insider Report for AMEDISYS INC (AMED)
- Reporting relationship
- President & COO
- Issuer ticker
- AMED
- Reported as of
- 02 Aug 2021
- Net transaction value
- -$326,544
- SEC form
- 4
- Accepted by SEC
- 04 Aug 2021, 21:01:22 UTC
- Prior SEC filing
- 06 Jul 2021
- Next SEC filing
- 22 Feb 2022
- Source filing
- View source filing
- Reporting owner signature
- /s/ Jennifer R. Guckert, pursuant to a power of attorney
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Christopher Gerard filed Form 4 for AMEDISYS INC (AMED) on 04 Aug 2021.
Change
- Previous filing in this sequence was filed on 06 Jul 2021.
- Current net transaction value: -$326,544.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
AMED
transaction
Common Stock
Sale
- Transaction value
- $25,744
- Shares
- -100
- Change %
- -0.26%
- Price
- $257.44
- Shares after
- 39,006
- Date
- 02 Aug 2021
- Ownership
- Direct
- Footnotes
- F1
AMED
transaction
Common Stock
Sale
- Transaction value
- $117,297
- Shares
- -450
- Change %
- -1.2%
- Price
- $260.66
- Shares after
- 38,556
- Date
- 02 Aug 2021
- Ownership
- Direct
- Footnotes
- F1, F2
AMED
transaction
Common Stock
Sale
- Transaction value
- $130,865
- Shares
- -500
- Change %
- -1.3%
- Price
- $261.73
- Shares after
- 38,056
- Date
- 02 Aug 2021
- Ownership
- Direct
- Footnotes
- F1, F3
AMED
transaction
Common Stock
Sale
- Transaction value
- $52,638
- Shares
- -200
- Change %
- -0.53%
- Price
- $263.19
- Shares after
- 37,856
- Date
- 02 Aug 2021
- Ownership
- Direct
- Footnotes
- F1, F4
AMED
holding
Common Stock
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- 279
- Date
- 02 Aug 2021
- Ownership
- Through 401(k) Plan
- Footnotes
- F5
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 5 footnotes
Footnote F1
These sales were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the reporting person.
Footnote F2
The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $260.38 to $261.16, inclusive. The reporting person undertakes to provide to Amedisys, Inc. (the "Issuer"), any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) to this Form 4.
Footnote F3
The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $261.39 to $262.34, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (3) to this Form 4.
Footnote F4
The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $263.16 to $263.215, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (4) to this Form 4.
Footnote F5
The information in this report is based on a plan statement dated as of June 30, 2021.